



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/622,869	07/18/2003	Suresh K. Tikoo	293102003600	2929
25226	7590	09/06/2007	EXAMINER	
MORRISON & FOERSTER LLP			CHEN, STACY BROWN	
755 PAGE MILL RD			ART UNIT	PAPER NUMBER
PALO ALTO, CA 94304-1018			1648	
MAIL DATE		DELIVERY MODE		
09/06/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/622,869	TIKOO, SURESH K.
	Examiner	Art Unit
	Stacy B. Chen	1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on June 22, 2006.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-64 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) _____ is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) 1-64 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input checked="" type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date: _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date: _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

Art Unit: 1648

DETAILED ACTION

1. The restriction requirement of April 30, 2007 is vacated. A new restriction is set forth as detailed below (see attached Interview Summary). Claims 1-64 are pending.

Election/Restrictions

2. Restriction to one of the following inventions is required under 35 U.S.C. 121.

Claims 1, 4, 5, 8, 11-14, 17-39 and 56-58 link(s) inventions I-XII. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claims 1, 4, 5, 8, 11-14, 17-39 and 56-58. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions **shall** be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104.

Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

- I. Claims 2, 6, 9 and 15, drawn to a motif comprising **AAATT**, classified in class 536, subclass 23.1.
- II. Claims 2, 6, 9 and 15, drawn to a motif comprising **ATT**, classified in class 536, subclass 23.1.
- III. Claims 2, 6, 9 and 15, drawn to a motif comprising **TATT**, classified in class 536, subclass 23.1.
- IV. Claims 2, 6, 9 and 15, drawn to a motif comprising **TATTTTTT**, classified in class 536, subclass 23.1.
- V. Claims 2, 6, 9 and 15, drawn to a motif comprising **TATATA**, classified in class 536, subclass 23.1.
- VI. Claims 2, 6, 9 and 15, drawn to a motif comprising **TTT**, classified in class 536, subclass 23.1.
- VII. Claims 3, 7, 10 and 16, drawn to a motif comprising **TATTTT**, classified in class 536, subclass 23.1.
- VIII. Claims 3, 7, 10 and 16, drawn to a motif comprising **ATATT**, classified in class 536, subclass 23.1.
- IX. Claims 3, 7, 10 and 16, drawn to a motif comprising **TTTA**, classified in 536, subclass 23.1.
- X. Claims 3, 7, 10 and 16, drawn to a motif comprising **AAATTTTA**, classified in class 536, subclass 23.1.
- XI. Claims 3, 7, 10 and 16, drawn to a motif comprising **ATTTTT**, classified in class 536, subclass 23.1.

XII. Claims 3, 7, 10 and 16, drawn to a motif comprising TATTTATT, classified in class 536, subclass 23.1.

[End of Linking Claims for Groups I-XII]

Claims 40 and 41 link(s) inventions XIII-XXIV. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claims 40 and 41.

XIII-XXIV. Claims 40-41, drawn to a method of eliciting an immune response, classified in class 435, subclass 5. Each of Groups XIII-XXIV represents one of the twelve (12) encapsidation sequences listed in claim 11.

[End of Linking Claims for Groups XIII-XXIV]

XXV. Claims 42-54 and 58, drawn to a recombinant porcine adenovirus vector comprising a deletion and/or addition of part or all of one or more E1 transcriptional control region, classified in class 435, subclass 320.1.

XXVI. Claim 55, drawn to a method of eliciting an immune response using a recombinant porcine adenovirus vector comprising a deletion and/or addition of part or all of one or more E1 transcriptional control region, classified in class 435, subclass 5.

XXVII. Claims 59-64, drawn to a method for preparing a porcine adenovirus, classified class 435, subclass 69.1.

3. The inventions are distinct, each from the other because of the following reasons:
 - a) Groups I-XII are all drawn to distinct nucleotide sequences having different motifs.

Each motif is patentably distinct because each sequence has different nucleic acid content, thus

presenting a serious search burden on the Office resources (see OG Notice attached to the previous restriction requirement).

b) Groups (I-XII) and (XIII-XXIV) are related as product and process of use; groups XXV and XXVI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the nucleotide sequences of Groups (I-XII) can be used as probes. The vectors of Group XXV can be used in a materially different method of use, such as in a detection assay.

c) Groups (I-XII) and XXV are unrelated inventions. The deletion in the viruses of Group XIV does not correspond to the deletions referred to in Groups I-XII. A search for both sets of viruses would be a serious burden because literature pertinent to one Group will not necessarily reveal the other Group.

d) Groups (I-XII) and XXVI are unrelated inventions, as are Groups (XIII-XXIV) and XXV. The sequences/viruses of Groups I-XII are not required to practice the method of Group XXVI. Likewise, the viruses of Group XXV are not required to practice the method of Groups (XIII-XXIV).

e) Inventions (I-XII) and XXVII are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the vectors/viruses can be made by site-directed mutagenesis.

f) Inventions (XIII-XXIV), XXVI and XXVII are all distinct methods. Methods of inducing an immune response with the sequences/vectors of (XIII-XXIV) are not expected to induce the same immune response as the viruses of Group XXVI. Further, the method of making the vectors does not require the method of inducing an immune response, or vice versa.

Because these inventions are distinct for the reasons given above and the literature and sequence search required for one Group is not co-extensive for any other Group, and therefore a serious burden, restriction for examination purposes as indicated is proper. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an

Art Unit: 1648

elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See “Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b),” 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Conclusion

5. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The

Art Unit: 1648

examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/Stacy B. Chen/ 8-30-2007
Primary Examiner, TC1600